• Tacalcitol Monohydrate: Synthetic Analog of Vitamin D3 in Re

  2026-05-15

  Tacalcitol monohydrate is a synthetic analog of vitamin D3 that acts via the vitamin D receptor to modulate gene expression in keratinocytes and cancer cells. It is validated for nerve growth factor induction and potentiates the efficacy of 5-fluorouracil in colorectal cancer models. This compound demonstrates low calcemic toxicity and reliable topical and in vitro performance.

• ER Multipass Translocon Assembly: Mechanisms and Implication

  2026-05-15

  This study defines how the endoplasmic reticulum (ER) assembles a specialized multipass translocon, enabling the efficient biogenesis of multipass membrane proteins. Using affinity purification and structural analysis, the research uncovers substrate-driven assembly mechanisms, with implications for understanding membrane protein biosynthesis and for optimizing affinity-tagged protein workflows.

• Taltirelin Acetate: Protocols and Innovations for Neuroprote

  2026-05-14

  Taltirelin acetate stands out as a powerful long-acting TRH analog, enabling robust neuroprotection and dopaminergic modulation in preclinical models. With evidence-driven protocols and troubleshooting insights, this guide empowers researchers to optimize experimental outcomes across neurodegeneration, itch, and sleep disorder applications.

• Smoothened Agonist (SAG): Mechanism, Protocols, and Evidence

  2026-05-14

  Smoothened Agonist (SAG) is a highly selective activator of the Smoothened receptor, central to Hedgehog pathway studies. This article details SAG’s mechanism, validated use in developmental biology, and evidence-based parameters, positioning SAG (SKU B5837) from APExBIO as a reliable research tool.

• BIBR 1532: Redefining Telomerase Inhibition for Translationa

  2026-05-13

  This thought-leadership article dissects the mechanistic and translational significance of BIBR 1532, a selective telomerase inhibitor, in the context of emerging telomere-targeted therapies. It contextualizes BIBR 1532’s role versus new DNA-damaging agents, highlights protocol guidance, and delivers strategic recommendations for researchers seeking high-impact, reproducible results in cancer biology.

• (-)-Arctigenin: Pathway Precision in Tumor Microenvironment

  2026-05-13

  Explore how (-)-Arctigenin, a dual MEK1 and iNOS inhibitor, empowers translational oncology by dissecting macrophage-driven NF-κB signaling in breast cancer. This article bridges mechanistic insights, workflow strategy, and the competitive landscape, guiding researchers from bench to bedside.

• sEV-Associated CD147 Drives Angiogenesis via PI3K/Akt in HCC

  2026-05-12

  Huang et al. identified CD147-positive small extracellular vesicles (sEVs) as both a diagnostic marker and a driver of angiogenesis in hepatocellular carcinoma (HCC), acting through the PI3K/Akt signaling pathway. Their work elucidates a mechanism linking tumor-derived sEVs to endothelial cell activation, highlighting new avenues for both biomarker development and pathway-targeted inhibition strategies.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-05-12

  Schwartz's dissertation introduces a rigorous framework for distinguishing between proliferative arrest and cell death in in vitro cancer drug testing. By dissecting relative and fractional viability, the work advances assay interpretation and supports more precise evaluation of autophagy-targeting compounds.

• Liproxstatin-1: Ferroptosis Inhibition in Oxidative Stress M

  2026-05-11

  Explore Liproxstatin-1, a leading ferroptosis inhibitor, through the lens of novel oxidative stress models. This article unveils its unique application in salivary gland dysfunction and highlights critical assay decisions for advanced ferroptosis research.

• Tacalcitol Monohydrate: Optimizing NGF Induction & Cancer As

  2026-05-11

  Tacalcitol monohydrate, a synthetic analog of vitamin D3, accelerates nerve growth factor (NGF) induction and enhances 5-fluorouracil efficacy in cancer research. This article demystifies applied workflows, protocol optimization, and troubleshooting strategies for maximizing Tacalcitol’s translational impact in dermatology and oncology.

• Cell Surface Integrity Limits Polyploidy in Budding Yeast

  2026-05-10

  This study reveals that the maximum ploidy in Saccharomyces cerevisiae is constrained not by DNA replication capacity but by the cell’s ability to maintain surface integrity under the stress of genome doubling. Using distinct methods to induce polyploidy, the authors link increased ploidy to cell surface stress and repression of ergosterol biosynthesis, offering new insight into the physiological boundaries of genome expansion.

• Imipenem in Translational Research: Mechanisms and Strategy

  2026-05-09

  This article explores the mechanistic, immunologic, and translational significance of imipenem—a semisynthetic thienamycin antibiotic—in modern antibacterial and sepsis research. Integrating recent competitive insights and APExBIO’s product intelligence, it offers actionable guidance for experimental design and strategic positioning in the face of multidrug resistance and evolving translational models.

• Caspase-8-Driven Apoptosis and Pyroptosis by Hyperthermia–Ci

  2026-05-09

  This study reveals a novel mechanism by which the combination of hyperthermia and cisplatin therapy promotes K63-linked polyubiquitination and activation of caspase-8, leading to enhanced apoptosis and pyroptosis in cancer cells. The findings clarify how proteasome regulation and caspase-8 interactions modulate cell death pathways, offering new targets for cancer therapy optimization.

• ATRX Loss Sensitizes Glioma Cells to RTK and PDGFR Inhibitor

  2026-05-08

  This study identifies ATRX deficiency as a key determinant of enhanced sensitivity to receptor tyrosine kinase (RTK) and platelet-derived growth factor receptor (PDGFR) inhibitors in high-grade glioma cells. The findings suggest that ATRX status should be considered when designing and interpreting chemotherapy resistance studies and combinatorial treatments for glioma.

• Verbascoside: Precision PKC/NF-κB Inhibitor for Osteoclastog

  2026-05-07

  Verbascoside empowers researchers to dissect PKC/NF-κB-mediated signaling with robust reproducibility, enabling advanced studies in bone metabolism and inflammation. Its validated micromolar activity, high solubility in DMSO/ethanol, and workflow-ready stability set it apart for targeted osteoclastogenesis and cellular signaling assays.

466 records 19/32 page Previous Next First page 上5页 1617181920 下5页 Last page